At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 493 enrolled
Drug / intervention
insulin degludec +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
In Brief
A Phase 3 clinical trial evaluating insulin degludec, insulin glargine, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 1. Completed, enrolled 493 participants across 82 sites in 7 countries.
Detailed Summary
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 1
CountriesBelgium, Germany, Greece, Norway, Poland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionNov 2010
Study CompletionMay 2011
TodayJul 2026
First PostedMar 3, 2010
Enrollment StartMar 1, 2010
Primary CompletionNov 1, 2010
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.3 years ago
Interventions
insulin degludecdrug
Injected subcutaneously (under the skin) once daily
insulin glarginedrug
Insulin glargine injected subcutaneously (under the skin) once daily
insulin aspartdrug
At least three daily doses at meal-time